Chronic kidney disease Hypercholesterolemia
Conditions
Interventions
Statin group: Pitavastatin is administrated and dosage will be We increased or decreased appropriately to reach the target LDL-C level (100mg/dl).
Control group: Lipid-lowering therapy is performed by
Sponsors
Department of Medical Science and Cardiorenal Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Chronic kidney disease patients with albuminuria (urine albumin excretion ratio, UACR >= 30 mg/g-creatinine) 2)Patient who is equal to or more than LDL-C 100mg/dL 3)Outpatients
Exclusion criteria
Exclusion criteria: 1)patient with less than eGFR 15mL/min/1.73m2 2)Patients meeting the contraindications or relative contraindications for pitavastatin 3)malignant tumor patient and the patient who have an anamnesis within five years 4)patient who developed cerebrovascular disorder within one month 5)patients with hypothyroidism, hereditary muscular disorder (muscular dystrophy), and medicine-related muscle disorder 6)Patients currently taking lipid lowering therapy 7)abnormal glycemia 8)angina 9)Patients participating in other studies 10)Patients ineligible for the study determined by doctors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percent changes in eGFR from baseline Urinary protein excretion (UACR) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Percent changes in TC,LDL-C,HDL-C,TG 2)Percent changes in Glucose,HbA1c, 3)Percent changes in hs-CRP 4)Percent changes in Pentosidine,L-FABP 5)Ambulatory BP monitering,PWV,ABI, central blood pressure | — |
Countries
Japan
Contacts
Public ContactKouichi TAMURA
Yokohama City University School of Medicine Department of Cardiorenal Medicine
Outcome results
None listed